Close menu

December 28th, 2023 | 07:30 CET

Morphosys with 50% risk? BioNTech and Defence Therapeutics share with positive news

  • Biotechnology
  • Pharma
Photo credits: BASF SE

Will the Morphosys share price halve? Analysts believe this is possible, although the German biotech veteran has been one of the winners in the sector this year. Overall, biotech shares were not among the favorites of investors in 2023. Nevertheless, the billion-dollar takeover of Karuna Therapeutics by Bristol-Myers Squibb announced yesterday gives the sector hope for a better performance in 2024. Today, we are focusing on three companies of different sizes, including Morphosys and Defence Therapeutics. The biotech company with a focus on immuno-oncology is closing the year with further positive news. The FDA has given the green light for the start of trials next year, which could open up a market worth billions. BioNTech has several pieces of positive news. Here, too, the FDA has made a positive statement, and the Company has achieved a milestone victory against CureVac.

time to read: 4 minutes | Author: Fabian Lorenz

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Defence Therapeutics: Billion-dollar market in focus

    Defence Therapeutics shareholders can look forward to an exciting 2024. Just before Christmas, the biotech company focusing on immuno-oncology received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical trial of its new drug AccuTOX®. This is an injectable anti-cancer molecule for the treatment of solid tumors and a further development of the original Accum™ molecule. According to Data Bridge Market Research, the market for the treatment of solid tumors was worth around USD 210 billion in 2021. By 2029, significant double-digit growth is forecasted, and the volume will shoot up to over USD 900 billion.

    In preclinical tests with T-cell lymphoma, melanoma or breast cancer, AccuTOX® has already demonstrated limited tumor growth and complete responses in 70% of treatments. Sébastien Plouffe, President and CEO of Defence Therapeutics, stated: "We are very proud and excited and look forward to the start of the Phase I trial. This trial aims to test one of our lead compounds and most promising therapeutic candidates for the treatment of solid tumors for the benefit of cancer patients. Defence is now entering the clinical phase."

    BioNTech: Positive news at the end of the year

    BioNTech has had several positive announcements in the past few days alone. Firstly, the Federal Patent Court ruled in BioNTech's favor in the patent dispute with CureVac. However, CureVac has announced an appeal, and the ruling only concerns one of eight property rights. The news, therefore, had little impact on the share.

    More important are the operational reports from the leading German biotech company. As with Defence Therapeutics, there is also positive news from the FDA. The US Food and Drug Administration has granted breakthrough therapy status to BioNTech's active ingredient BNT323/DB-1303 for the treatment of advanced endometrial cancer in patients who have progressed during or after treatment with immune checkpoint inhibitors. BNT323/DB-1303 is a next-generation antibody-drug conjugate that targets a cell surface protein in various tumor types. The FDA's decision is based on encouraging initial data from a Phase I/II study in patients with advanced uterine cancer.

    Prof. Özlem Türeci, CMO and co-founder of BioNTech: "The Breakthrough Therapy designation for BNT323/DB-1303 demonstrates the potential of our ADC candidate to address the current challenges in the treatment of patients with advanced HER2-expressing endometrial cancer who have progressed on multiple lines of systemic therapy. Survival rates for these patients remain low, and the medical need for new and more effective treatments remains high." Endometrial or uterine cancer is the second most common gynecologic cancer worldwide, with over 400,000 cases per year - and unfortunately, the trend is rising. While localized early-stage disease can be cured by surgery, the five-year survival rate for patients with advanced, metastatic or recurrent disease is only 18.45%.

    A few days before the FDA announcement, BioNTech had reported on the inauguration of a new site in Rwanda. It took place on the occasion of the construction of the first production unit called BioNTainer. The facility is part of BioNTech's effort to build an extensive vaccine ecosystem in Africa. In addition to the production of vaccines, research and development, clinical trials and the training of specialists will also take place locally in the future.

    A few days before the FDA announcement, BioNTech had reported on the inauguration of a new site in Rwanda. It took place on the occasion of the construction of the first production unit called BioNTainer. The facility is part of BioNTech's effort to build an extensive vaccine ecosystem in Africa. In addition to the production of vaccines, research and development, clinical trials and the training of specialists will also take place locally in the future.

    Morphosys: Could the share price halve?

    Morphosys shares have been a highlight in the biotech sector this year. The shares of the German biotech veteran have more than doubled in the current year and are trading at over EUR 32. Only in November was there a slump from around EUR 31 to EUR 16. However, this setback was recovered within a few weeks. The reason for the temporary slump in the share price was preliminary study data on the promising drug pelabresib.

    The entire Phase III trial of the active substance against myelofibrosis was published recently. Myelofibrosis is characterized by an enlarged spleen, anaemia, bone marrow fibrosis and disease-related symptoms. Morphosys announced that all features were improved with the combination of pelabresib and ruxolitinib compared to placebo plus ruxolitinib, the standard of care for myelofibrosis. Significant improvements in both key secondary endpoints were observed with the pelabresib combination in intermediate-risk patients, who make up over 90% of the MANIFEST-2 population. Two days after the results, Morphosys announced a 10% capital increase. This was successfully implemented and raised around EUR 100 million for the Company.

    However, analysts remain skeptical. Goldman Sachs even considers it possible that the share price will almost halve. Their target price is EUR 17.50. The valuation has been adjusted in line with the higher number of shares and the expected losses in the coming years. Deutsche Bank's price target of EUR 25 is also slightly higher than the current share price. At least it is positive that Morphosys should be fully financed for the coming years thanks to the successful capital increase.

    With a market capitalization of around CAD 100 million, Defence Therapeutics is the smallest of the companies discussed. After consistently working on the exciting pipeline in 2023, the share price should rise again with a sustained positive news flow. In addition, the Company is a takeover candidate. This does not apply to BioNTech due to its shareholder structure. Instead, BioNTech, with its well-filled treasury, is often active as an acquirer itself. Morphosys, on the other hand, is always good for a surprise - both positive and negative.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.


    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?


    Commented by Fabian Lorenz on February 14th, 2024 | 07:00 CET

    Plug Power, Bayer, Defense Metals: Shares in panic mode

    • Mining
    • RareEarths
    • Hydrogen
    • Pharma

    Is everything not so bad at Plug Power, after all? In January, the hydrogen specialist triggered panic among investors with an announced capital increase. Now, the CEO is suddenly rowing back. So, should one buy the stock now? One analyst advises caution. Bayer shareholders are also in panic mode. The downward trend of the share simply cannot find a bottom. Even at this level, analysts are cautious. Defense Metals, on the other hand, is benefiting from panic - because this concerns the supply of rare earths. The dependence on China is enormous. Defense Metals aims to change this with its rare earth project in Canada. The Company CEO expressed confidence in an interview, stating that an important agreement has been reached with the local population, and important dates are on the horizon.